Growth Hormone and Brain Functioning After Traumatic Brain Injury

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (201 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-04-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injuryto severebraintraumaticcoronary
  Phrases that lowered it: growthpatientstumorsperformancemultiple
• Accepts healthy volunteers: No (raises risk) · Who can join
• Responsible party: sponsor investigator (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 10.2% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 97.0% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Allocation: non randomized (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury. NCT00766038 · started 2008 · scored riskier than 63% of active trials completed
• Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI) NCT02114775 · started 2014 · scored riskier than 38% of active trials completed
• Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency NCT01007071 · started 2009 · scored riskier than 76% of active trials completed
• Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury NCT01329757 · started 2011 · scored riskier than 26% of active trials completed
• The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment NCT02553603 · started 2017 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.